Partner With Us NRI

Suven Pharmaceuticals Ltd share Price

Company details

6M Return 7.60%
1Y Return -23.33%
Mkt Cap.(Cr) 11,953.10
Volume 2,547
Div Yield 1.06%
OI Chg %
Volume 2,547

Open Free Trading Account Online with ICICIDIRECT

CRAMs continue to deliver, outlook stable…

About The Stock

    Dedicated CRAMs that supports the global life sciences industry & fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing.

    • In FY22, CRAMs Pharma vertical contributed 59% of sales. Besides CRAMs Pharma, Suven has also has developed & supplied intermediates/technical for specialty chemicals CRAMs, which accounted for 35% of sales
    • Suven is currently on a three pronged investment plan, 1) relocating R&D centre, 2) replacement and upgradation of blocks at Suryapet facility and 3) additional new block in line with FDA regulations at Pashamylaram facility


    Suven reported strong Q4 numbers driven by strong traction in both Spec Chem and Pharma CRAMs.

    • Sales were up 40% YoY to ₹ 364 crore
    • EBITDA was at ₹ 157 crore, up 68% YoY with margins at 43%
    • Consequent PAT was at ₹ 92 crore (up 10% YoY)

Click here for full recommendation

Research view on more stocks

Suven Pharmaceuticals Ltd.

Q3FY22 Quarterly Result Announced for Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals declares Q3FY22 result:

  • The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
  • The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021.
  • The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.
  • The Board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma Pvt. Ltd., an SEZ unit in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
  • The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.



Result PDF

View Other Company Results


Investment recommendation

CRAMs continue to deliver, outlook stable…

Call Date

09 Aug 2022

Entry Price


Target Price



12-18 Month



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax




Suven Pharmaceuticals Ltd Stocks COMPARISION


Equity Capital: 1,527.18 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,948.47 4,147.77
LAST 3M 50,808.43 -11,347.14
LAST 6M 78,521.89 15,105.83
LAST 12M 169,956.63 -37,974.87

Suven Pharmaceuticals Ltd Information

Stock PE (TTM)


Promoter Holding


Book Value






Registered Address

8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034

Tel : 91-40-23549414/1142/3311
Email : info:suvenpharm.com
Website : http://www.suvenpharm.com


KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543064
Book Closure Date (Month) :
BSE Group : A
ISIN : INE03QK01018

FAQ’s on Suven Pharmaceuticals Ltd Shares

You can buy Suven Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Suven Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 27, 2023 04:01 PM the closing price of Suven Pharmaceuticals Ltd was ₹ 469.55.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 27, 2023 04:01 PM, the market cap of Suven Pharmaceuticals Ltd stood at ₹ 11,953.10.

The latest PE ratio of Suven Pharmaceuticals Ltd as of Mar 27, 2023 04:01 PM is 31.6

The latest PB ratio of Suven Pharmaceuticals Ltd as of Mar 27, 2023 04:01 PM is 0.13

The 52-week high of Suven Pharmaceuticals Ltd is ₹ 631.15 while the 52-week low is ₹ 387.50

According to analyst recommendations, Suven Pharmaceuticals Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app